Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-label Phase II/III Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel / HB1801 in Patients With sqNSCLC

NCT06319313 is registered in ClinicalTrials.gov with Shanghai JMT-Bio Inc. as lead sponsor.

NCT NCT06319313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06319313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-label Phase II/III Study of The Safety, Tolerability and Efficacy of JMT101 Combined With Docetaxel / HB1801 in Patients With sqNSCLC
Lead sponsor
Shanghai JMT-Bio Inc.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
May 1, 2024
Completion date
December 1, 2027
Enrollment
534 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell non-small cell lung cancer